Mapping Cancer Response using Organoids and Mass cytometry

Project description

Cancer patient organoids to guide treatment

Tumours are characterised by great heterogeneity which often impedes drug effectiveness. Therefore, cancer models used in drug development must reflect disease properties in order to recapitulate their drug response. The EU-funded MaCaROM project proposes to use organoids derived from breast cancer patient samples to meet this challenge. Using mass cytometry, scientists will evaluate response of heterogeneous cancer models to different FDA-approved drugs at the single-cell level. Results will provide important information on drug sensitivity and resistance, supporting treatment decisions for improved clinical outcome and increased patient survival.

Fields of science

• medical and health sciences › clinical medicine › oncology › breast cancer
• medical and health sciences › health sciences › personalized medicine
• medical and health sciences › medical biotechnology › cells technologies

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAT ZURICH

Net EU contribution

€ 191 149,44

Address

Ramistrasse 71
8006 Zurich
Switzerland

Region

Schweiz/Suisse/Svizzera › Zürich › Zürich

Activity type

Higher or Secondary Education Establishments

Links

Non-EU contribution

€ 0,00